Nokea
Which name identifies a drug listed by the US Food and Drug Administration (FDA)?
- A. Brand
- B. Nonproprietary
- C. Official
- D. Trademark
Correct Answer: C
Rationale: The official name is the name under which a drug is listed by the FDA. The brand name, or trademark, is the name given to a drug by its manufacturer. The nonproprietary, or generic, name is provided by the United States Adopted Names Council.
You may also like to solve these questions
Which statement is not correct regarding acarbose:
- A. Is for internal use
- B. Inhibiting alfa glucosidase
- C. Inhibits carbohydrates absorbtion in the gut
- D. Is effective for diabetes mellitus type I
Correct Answer: D
Rationale: Acarbose is primarily effective for type 2 diabetes by delaying carbohydrate absorption, not type 1, which relies on insulin deficiency.
Adherence to beta blocker therapy may be affected by their:
- A. Short half-lives requiring twice daily dosing
- B. Tendency to elevate lipid levels
- C. Effects on the male genitalia, which may produce impotence
- D. None of the above
Correct Answer: C
Rationale: Impotence is a known side effect that can reduce adherence to beta blockers.
A 25-year-old woman comes to the clinic complaining of rapid heart rate and easy fatigability. Laboratory results reveal low hemoglobin levels and microcytic red blood cells. The most suitable therapy for her condition will be:
- A. Folic acid
- B. Epoiten alfa
- C. Ferrous sulfate
- D. Vitamin B12
Correct Answer: C
Rationale: Microcytic anemia suggests iron deficiency; ferrous sulfate is the standard treatment.
Not an antidepressant
- A. Amitryptilline
- B. Fluoxetin
- C. Trazodone
- D. Pimozide
Correct Answer: D
Rationale: Pimozide is an antipsychotic, not an antidepressant.
A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a...
- A. Physiological antagonist
- B. Competitive antagonist
- C. Noncompetitive antagonist
- D. Partial agonist
Correct Answer: C
Rationale: Noncompetitive antagonists reduce maximal response (efficacy) without shifting potency, matching the description.